法尼酯X受体：从结构到潜在临床应用 - Suppr

Suppr

超能文献

Farnesoid X receptor: from structure to potential clinical applications.

作者信息

Pellicciari Roberto, Costantino Gabriele, Fiorucci Stefano

机构信息

Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Via del Liceo 1, I-06123 Perugia, Italy.

出版信息

J Med Chem. 2005 Aug 25;48(17):5383-403. doi: 10.1021/jm0582221.

DOI:10.1021/jm0582221

PMID:16107136

Abstract

摘要

相似文献

Farnesoid X receptor: from structure to potential clinical applications.法尼酯X受体：从结构到潜在临床应用

J Med Chem. 2005 Aug 25;48(17):5383-403. doi: 10.1021/jm0582221.

Targeting farnesoid X receptor for liver and metabolic disorders.以法尼醇X受体为靶点治疗肝脏和代谢紊乱疾病。

Trends Mol Med. 2007 Jul;13(7):298-309. doi: 10.1016/j.molmed.2007.06.001. Epub 2007 Jun 27.

FXR: a promising target for the metabolic syndrome?法尼酯X受体：代谢综合征的一个有前景的靶点？

Trends Pharmacol Sci. 2007 May;28(5):236-43. doi: 10.1016/j.tips.2007.03.002. Epub 2007 Apr 6.

Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity.人源LRH-1 DBD-DNA复合物的晶体结构揭示受体活性需要Ftz-F1结构域定位。

J Mol Biol. 2005 Dec 16;354(5):1091-102. doi: 10.1016/j.jmb.2005.10.009. Epub 2005 Oct 27.

Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"?核受体配体与辅因子募集：是否有一个共激活因子“待命”？

Mol Cell. 2003 Apr;11(4):850-1. doi: 10.1016/s1097-2765(03)00133-3.

A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease.核受体激活的动态机制及其在人类疾病中的紊乱。

Nat Struct Biol. 2003 Feb;10(2):136-40. doi: 10.1038/nsb892.

Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.胆汁酸、法尼醇X受体、动脉粥样硬化与代谢控制

Curr Opin Lipidol. 2007 Jun;18(3):289-97. doi: 10.1097/MOL.0b013e3281338d08.

Recognition of LXXLL by ligand binding domain of the Farnesoid X receptor in molecular dynamics simulation.在分子动力学模拟中，法尼醇X受体的配体结合结构域对LXXLL的识别。

J Chem Inf Model. 2006 Nov-Dec;46(6):2623-30. doi: 10.1021/ci060112v.

Orphan nuclear receptors adopted by crystallography.通过晶体学确定的孤儿核受体

Curr Opin Struct Biol. 2005 Dec;15(6):708-15. doi: 10.1016/j.sbi.2005.10.009. Epub 2005 Nov 2.

Molecular dynamics simulations of human LRH-1: the impact of ligand binding in a constitutively active nuclear receptor.人源肝脏受体同源物-1的分子动力学模拟：配体结合对组成型活性核受体的影响

Biochemistry. 2008 May 6;47(18):5205-15. doi: 10.1021/bi7025084. Epub 2008 Apr 15.

引用本文的文献

Synergistic action of cilnidipine and bexarotene in mitigating cholestatic liver damage: role of FXR signaling cascade.西尼地平与贝沙罗汀在减轻胆汁淤积性肝损伤中的协同作用：法尼醇X受体信号级联反应的作用

Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 17. doi: 10.1007/s00210-025-04061-7.

Structural basis for the asymmetric binding of coactivator SRC1 to FXR-RXRα and allosteric communication within the complex.共激活因子SRC1与FXR-RXRα不对称结合的结构基础及复合物内的变构通讯。

Commun Biol. 2025 Mar 13;8(1):425. doi: 10.1038/s42003-025-07854-x.

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.胆汁酸激活受体：整合非酒精性脂肪性肝病中的免疫与代谢调节

Liver Res. 2021 Sep 2;5(3):119-141. doi: 10.1016/j.livres.2021.08.003. eCollection 2021 Sep.

Tailoring obeticholic acid activity by iridium(III) complex conjugation to develop a farnesoid X receptor probe.通过铱（III）配合物共轭来调整奥贝胆酸活性以开发法尼醇X受体探针。

J Adv Res. 2025 May;71:307-316. doi: 10.1016/j.jare.2024.10.028. Epub 2024 Oct 28.

Delineating the role of nuclear receptors in colorectal cancer, a focused review.阐述核受体在结直肠癌中的作用：一篇重点综述

Discov Oncol. 2024 Feb 19;15(1):41. doi: 10.1007/s12672-023-00808-x.

Overview of Ursolic Acid Potential for the Treatment of Metabolic Disorders, Autoimmune Diseases, and Cancers via Nuclear Receptor Pathways.熊果酸通过核受体途径治疗代谢紊乱、自身免疫性疾病和癌症的潜力概述。

Biomedicines. 2023 Oct 19;11(10):2845. doi: 10.3390/biomedicines11102845.

Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors.利用齐墩果酸及其衍生物作为代谢核受体调节剂。

Biomolecules. 2023 Sep 28;13(10):1465. doi: 10.3390/biom13101465.

Structure Optimization of 12β--γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy.12β-γ-谷氨酰齐墩果酸衍生物的结构优化产生用于非酒精性脂肪性肝炎治疗的强效法尼醇X受体拮抗剂/调节剂

Pharmaceuticals (Basel). 2023 May 17;16(5):758. doi: 10.3390/ph16050758.

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice.一种三联法尼醇X受体和过氧化物酶体增殖物激活受体α/δ激活剂可逆转饮食诱导的小鼠非酒精性脂肪性肝炎中的肝纤维化。

Commun Chem. 2020 Nov 13;3(1):174. doi: 10.1038/s42004-020-00411-z.

FXR: structures, biology, and drug development for NASH and fibrosis diseases.FXR：NASH 和纤维化疾病的结构、生物学和药物研发。

Acta Pharmacol Sin. 2022 May;43(5):1120-1132. doi: 10.1038/s41401-021-00849-4. Epub 2022 Feb 25.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验